Compositions of modulators of acyl-CoA lysocardiolipin acyf transferase 1 (ALCATl ) expression, function or activity are provided. In particular, inhibitors of ALCATl are useful in treating metabolic diseases, cardiac diseases and, in general diseases associated with mitochondrial dysfunction. Assays for identification of novel ALCATl modulators are provided.